Antibe Therapeutics Inc
TSX:ATE
Balance Sheet
Balance Sheet Decomposition
Antibe Therapeutics Inc
Antibe Therapeutics Inc
Balance Sheet
Antibe Therapeutics Inc
| Mar-2014 | Mar-2015 | Mar-2016 | Mar-2017 | Mar-2018 | Mar-2019 | Mar-2020 | Mar-2021 | Mar-2022 | Mar-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
3
|
0
|
0
|
2
|
4
|
6
|
6
|
72
|
35
|
7
|
|
| Cash |
3
|
0
|
0
|
2
|
4
|
6
|
6
|
0
|
0
|
0
|
|
| Cash Equivalents |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
72
|
35
|
7
|
|
| Short-Term Investments |
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
20
|
32
|
|
| Total Receivables |
0
|
0
|
2
|
1
|
1
|
2
|
2
|
3
|
1
|
2
|
|
| Accounts Receivables |
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
1
|
0
|
|
| Inventory |
0
|
0
|
2
|
3
|
3
|
3
|
3
|
2
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
1
|
1
|
0
|
0
|
0
|
2
|
5
|
1
|
|
| Total Current Assets |
4
|
1
|
5
|
6
|
8
|
11
|
12
|
79
|
61
|
42
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Intangible Assets |
0
|
0
|
3
|
3
|
3
|
2
|
2
|
1
|
26
|
26
|
|
| Goodwill |
0
|
0
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
|
| Other Assets |
0
|
0
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
|
| Total Assets |
4
N/A
|
1
-82%
|
10
+1 116%
|
11
+12%
|
12
+16%
|
15
+19%
|
14
-7%
|
82
+491%
|
89
+9%
|
71
-21%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
0
|
0
|
1
|
2
|
2
|
2
|
5
|
2
|
3
|
3
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
1
|
0
|
0
|
|
| Short-Term Debt |
0
|
0
|
2
|
1
|
2
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
|
| Other Current Liabilities |
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
|
| Total Current Liabilities |
1
|
0
|
3
|
3
|
3
|
3
|
8
|
4
|
5
|
3
|
|
| Long-Term Debt |
0
|
0
|
2
|
3
|
0
|
2
|
0
|
0
|
0
|
0
|
|
| Deferred Income Tax |
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
1
|
1
|
2
|
2
|
28
|
28
|
28
|
|
| Total Liabilities |
1
N/A
|
0
-56%
|
6
+1 153%
|
7
+27%
|
5
-37%
|
7
+63%
|
10
+36%
|
31
+213%
|
32
+3%
|
30
-6%
|
|
| Equity | |||||||||||
| Common Stock |
7
|
8
|
13
|
16
|
30
|
37
|
50
|
112
|
140
|
141
|
|
| Retained Earnings |
6
|
10
|
12
|
16
|
27
|
38
|
57
|
76
|
101
|
120
|
|
| Additional Paid In Capital |
2
|
2
|
3
|
4
|
5
|
8
|
11
|
14
|
18
|
19
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
3
N/A
|
0
-90%
|
4
+1 068%
|
4
-11%
|
8
+125%
|
7
-7%
|
4
-49%
|
50
+1 230%
|
57
+13%
|
40
-29%
|
|
| Total Liabilities & Equity |
4
N/A
|
1
-82%
|
10
+1 116%
|
11
+12%
|
12
+16%
|
15
+19%
|
14
-7%
|
82
+491%
|
89
+9%
|
71
-21%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
3
|
4
|
8
|
11
|
20
|
24
|
29
|
46
|
52
|
53
|
|